Scancell (LON:SCLP) Shares Pass Above Fifty Day Moving Average - What's Next?

Key Points

• Scancell Holdings plc's stock has crossed above its fifty-day moving average of GBX 9.89, trading as high as GBX 10 during recent sessions.
• The company has a market capitalization of £103.57 million and a debt-to-equity ratio of -566.79, indicating significant insider ownership of 4.96%.
• Insider Martin Diggle purchased 44,944 shares at an average price of GBX 9, signaling confidence in the company's future performance.

Scancell Holdings plc (LON:SCLP - Get Free Report) shares crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of GBX 9.89 ($0.13) and traded as high as GBX 10 ($0.13). Scancell shares last traded at GBX 9.75 ($0.13), with a volume of 402,929 shares traded.

Scancell Price Performance

The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79. The company has a 50-day moving average of GBX 9.90 and a 200 day moving average of GBX 9.43. The stock has a market capitalization of £108.70 million, a PE ratio of -16.09 and a beta of 0.35.

Insider Activity at Scancell

In other news, insider Martin Diggle bought 44,944 shares of the firm's stock in a transaction that occurred on Tuesday, May 20th. The shares were purchased at an average price of GBX 9 ($0.12) per share, with a total value of £4,044.96 ($5,343.41). 4.96% of the stock is currently owned by company insiders.

Scancell Company Profile

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.